CSIMarket Company Name, Ticker, Customers, else..
 
Bridgebio Pharma Inc   (NASDAQ: BBIO)
Other Ticker:  
 
 
Price: $34.7700 $0.86 2.536%
Day's High: $35.09 Week Perf: 5.33 %
Day's Low: $ 33.09 30 Day Perf: -5.53 %
Volume (M): 3,461 52 Wk High: $ 39.47
Volume (M$): $ 120,332 52 Wk Avg: $28.06
Open: $33.39 52 Wk Low: $21.62



 Market Capitalization (Millions $) 6,468
 Shares Outstanding (Millions) 186
 Employees 260
 Revenues (TTM) (Millions $) 222
 Net Income (TTM) (Millions $) -543
 Cash Flow (TTM) (Millions $) 289
 Capital Exp. (TTM) (Millions $) 9

Bridgebio Pharma Inc
BridgeBio Pharma Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing targeted therapies to treat genetic diseases. The company utilizes a diversified approach to drug development, targeting a range of diseases including oncology, cardiology, dermatology, neurology, and endocrinology. BridgeBio operates through a subsidiary model, with a portfolio of subsidiaries that are controlled by the company and dedicated to specific genetic diseases. The company aims to apply innovative science to address the unmet needs of patients with genetic diseases and bring transformative therapies to market.


   Company Address: 3160 Porter Drive Palo Alto 94304 CA
   Company Phone Number: 391-9740   Stock Exchange / Ticker: NASDAQ BBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        1.92% 
PFE   -0.65%    
REGN   -0.68%    
TEVA   -3.65%    
VRTX   -2.06%    
VTRS   -1.08%    
• View Complete Report
   



Management Announcement

BridgeBio Pharma Faces Tumultuous Path: High Hopes and Deep Losses in Genetic Disease Treatments

Published Mon, Jan 13 2025 4:00 PM UTC

BridgeBio Pharma: Navigating the Dichotomy of Rising Demand and Pertinent Financial LossesIn the realm of biotechnology, where innovation is as commendable as it is hazardous, BridgeBio Pharma Inc. stands at a crossroads. The Palo Alto-based company has recently reported remarkable strides in its portfolio, particularly concerning treatments for genetic diseases such as tr...
Product Service News

Breakthroughs in Genetic Disease Treatments Highlighted by BridgeBio Pharmas Advances in ATTR-CM and Achondroplasia ...

Published Fri, Dec 13 2024 12:18 PM UTC

In the ever-evolving landscape of biopharmaceuticals, the emergence of innovative treatments for genetic diseases offers hope to countless individuals and families grappling with serious medical challenges. BridgeBio Pharma, Inc., a Palo Alto-based biopharmaceutical company with a focus on genetic diseases, is making significant strides with its groundbreaking therapies, par...
Clinical Study

FDA Approves Attruby (Acoramidis) as the First Near-Complete Stabilizer of TTR, Significantly Improving Outcomes for ...

Published Sat, Nov 23 2024 12:12 AM UTC

In a groundbreaking development in the field of cardiology, the U.S. Food and Drug Administration (FDA) has officially approved Attruby (acoramidis), marking a significant milestone in the treatment of patients suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This approval heralds the emergence of Attruby as the first and only therapeutic agent with a designate...
Clinical Study

for the BridgeBios Infigratinib Shines in Achondroplasia Study; Revenue Soars Past Competitors in Q2 202...

Published Mon, Nov 18 2024 10:30 AM UTC

Breakthrough in Achondroplasia Treatment: BridgeBio s Infigratinib Excels in Phase 2 PROPEL 2 Study While Revenues SurgeBridgeBio Pharma, a prominent figure in the biotechnology arena, has marked a significant milestone with the publication of its Phase 2 PROPEL 2 study results in the New England Journal of Medicine. The investigative study centered around infigratinib, a n...
Product Service News

Bridging Finance and Innovation How Portfolio Theory is Shaping Biomedical Advancements

Published Tue, Nov 5 2024 12:30 PM UTC

In a notable advancement within the intersection of finance and biotechnology, BridgeBio Pharma has announced the publication of a compelling case study exploring the implications of portfolio theory on biomedical innovation. This scholarly work appears in the esteemed Journal of Portfolio Management and stands as a testament to the innovative approaches BridgeBio employs in...






Bridgebio Pharma Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com